rVSVΔG-ZEBOV-GP, V920 + Chikenpox or Varicella vaccine (VARILRIX)
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ebola Virus Disease
Conditions
Ebola Virus Disease
Trial Timeline
Apr 9, 2021 → Aug 9, 2022
NCT ID
NCT05130398About rVSVΔG-ZEBOV-GP, V920 + Chikenpox or Varicella vaccine (VARILRIX)
rVSVΔG-ZEBOV-GP, V920 + Chikenpox or Varicella vaccine (VARILRIX) is a phase 1/2 stage product being developed by Merck for Ebola Virus Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05130398. Target conditions include Ebola Virus Disease.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05130398 | Phase 1/2 | Completed |
Competing Products
20 competing products in Ebola Virus Disease